Lanner announced that Complete Genomics has invested in its WITNESS predictive simulation platform. The agreement means WITNESS will simulate and optimise business processes at Complete Genomics to enhance the provision of highly accurate, human genome data, ready for interpretation, to biological researchers.
Having selected WITNESS based on its ability to rapidly model the complex, interconnected processes used to deliver accurate DNA sequencing, Matt Morenzoni, Biomolecular Systems Scientist, Complete Genomics comments, “In an industry driven by innovation, precision and speed it is imperative that the best business outcomes are found most effectively.”
Mandy Tague, Lanner director of business development, says, “By choosing predictive simulation to gain insight into the operations of their business, Complete Genomics will be able to make confident decisions that will allow them to meet the increasing demand for their services.”
She continues, “Experimenting with the firm's end-to-end service methods that include process automation, sample preparation, computing infrastructure, and service delivery technology allows Complete Genomics to maximise throughput. This provides the firm's research clients with highly accurate genomic data, assembled and annotated, ready for biological interpretation with optimum efficiency.”